Fresenius is a strong buy with a 60% Return on Revenue potential in the next 3 years, driven by earnings growth and strategic ...

Investors might want to bet on Fresenius (FMS), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Truist raised the firm’s price target on Fresenius Medical (FMS) to $25 from $23 and keeps a Hold rating on the shares as ...

Amicus™ high collection efficiency yields multiple products per donor for the lowest-cost platelet production. It is designed to adapt to the requirements of different collection settings. Let ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

In recent trading, shares of Fresenius Medical Care AG (Symbol: FMS) have crossed above the average analyst 12-month target price of $22.50, changing hands for $22.81/share. When a stock reaches ...

The Fresenius clinic, currently located in the basement of CentraCare — Rice Memorial Hospital, is moving to a new location ...

Fresenius Medical Care (NYSE:FMS – Free Report) had its price target lifted by Truist Financial from $23.00 to $25.00 in a research note published on Monday,Benzinga reports. Truist Financial ...

Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China. Further financial details of the partnership were not disclosed.

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...